MichaelJRobertsonMD
Oncology • Indianapolis, INHematologic Oncology
Associate Professor of Medicine, Indiana University
Dr. Robertson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
535 Barnhill Dr
# ROUTE473
Indianapolis, IN 46202Phone+1 317-944-5000Fax+1 317-944-3684
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1987 - 1990
University of ChicagoResidency, Internal Medicine, 1984 - 1987
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1984
Certifications & Licensure
IN State Medical License 1996 - 2025
IL State Medical License 1984 - 2003- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors Start of enrollment: 1997 Oct 01
- Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Publications & Presentations
PubMed
- 19 citationsPost-transplant lymphoproliferative disorder: Update on treatment and novel therapies.Suheil Albert Atallah-Yunes, Omar Salman, Michael J Robertson
British Journal of Haematology. 2023-05-01 - 3 citationsEpigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma.Suheil Albert Atallah-Yunes, Michael J Robertson, Utpal P Davé
Clinical Lymphoma, Myeloma & Leukemia. 2022-09-01 - 30 citationsCytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives.Suheil Albert Atallah-Yunes, Michael J Robertson
Frontiers in Immunology. 2022-01-01
Grant Support
- Mechanisms Of STAT4 Deficiency In The Immune System Of Cancer PatientsNational Cancer Institute2007–2011
- Recombinant Human Interleukin-18 For Treatment Of A Patient With MetastaticNational Center For Research Resources2005
- Rhu IL 12 After High Dose &Autologous Hematopoietic Stem CellsNational Center For Research Resources1999–2002
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
